Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 11:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 25 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: CYP Cocktail Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Interactions Between Cannabinoids and Cytochrome P450-Metabolized Drugs

NCT04201197
View directory record Official record
Conditions
Drug-Interactions
Interventions
Inje cocktail, THC Cannabis extract, THC/CBD Cannabis Extract
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 50 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Oct 21, 2026, 11:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Research Study to Investigate How a Study Medicine (NNC9204- 1177) Affects Blood Levels of Other Medicines in Healthy People

NCT04059367
View directory record Official record
Conditions
Healthy Volunteers, Overweight, Obesity
Interventions
NNC9204-1177, Cocktail of 5 already approved drugs
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 60 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2020 · Synced Oct 21, 2026, 11:26 AM EDT
Recruiting Phase 1 Interventional

An Early-Stage Study in Multiple Clinics of How Afimkibart May Affect the Body's Processing of Medicines That Rely on Cytochrome P450 Enzymes in Participants With Ulcerative Colitis

NCT07665723
View directory record Official record
Conditions
Active Ulcerative Colitis
Interventions
Afimkibart, Caffeine, Warfarin, Omeprazole, Dextromethorphan, Midazolam, Vitamin K
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Chula Vista, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 21, 2026, 11:26 AM EDT
Completed Phase 1 Interventional

Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis

NCT02397382
View directory record Official record
Conditions
Psoriasis
Interventions
Guselkumab, Midazolam, Warfarin, Omeprazole, Dextromethorphan, Caffeine
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
8
States / cities
Anniston, Alabama • North Hollywood, California • Orlando, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2017 · Synced Oct 21, 2026, 11:26 AM EDT
Completed Phase 1 Interventional Results available

A Study of Mirikizumab in Participants With Plaque Psoriasis

NCT03718884
View directory record Official record
Conditions
Psoriasis
Interventions
Drug Cocktail, Mirikizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Anaheim, California • DeLand, Florida • High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 29, 2024 · Synced Oct 21, 2026, 11:26 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Research Study on How UBT251 Affects Levels of Midazolam, Caffeine and Warfarin in the Blood of Participants With Excess Body Weight

NCT07710768
View directory record Official record
Conditions
Obesity, Overweight
Interventions
UBT251, Cocktail (Warfarin/Caffeine/Midazolam)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 21, 2026, 11:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study of Pacritinib and CYP450,Transporter Substrates, and CYP450 3A4 in Healthy Male Subjects

NCT05657613
View directory record Official record
Conditions
Drug Interactions
Interventions
CYP450 Cocktail and Transporter Substrates with Pacritinib, Part 2 -Group A Bosentan 125 mg (CYP450 3A4 inducer) with Pacritinib, Part 2 Group B - Fluconazole (CYP450 3A4 inhibitor) with Pacritinib
Drug
Lead sponsor
CTI BioPharma
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Oct 21, 2026, 11:26 AM EDT
Not yet recruiting Phase 1 Interventional

A Study of LY3873862 in Participants With Sporadic or Familial Amyotrophic Lateral Sclerosis (ALS).

NCT07883590
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Cytochrome P-450 Enzyme System
Interventions
LY3873862, CYP450 Drug Cocktail, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
San Francisco, California • Aurora, Colorado • Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 21, 2026, 11:26 AM EDT
Recruiting Phase 2 Interventional

A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

NCT05967689
View directory record Official record
Conditions
Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
Interventions
TAS6417, CYP Cocktail, Transporter Cocktail
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
18
States / cities
Birmingham, Alabama • Duarte, California • Boston, Massachusetts + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 21, 2026, 11:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Voxelotor CYP and Transporter Cocktail Interaction Study

NCT05981365
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Voxelotor, Bupropion, Repaglinide, Flurbiprofen, Omeprazole, Midazolam, Metformin, Furosemide, Rosuvastatin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 22, 2024 · Synced Oct 21, 2026, 11:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Drug-Drug Interaction Study Evaluating the Perpetrator Potential of DC-806 on Cocktails of CYP450 Enzyme and Transporter Substrates in Healthy Participants

NCT06092931
View directory record Official record
Conditions
Healthy Participants
Interventions
DC-806, Midazolam, Repaglinide, Digoxin, Rosuvastatin
Drug
Lead sponsor
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 21, 2026, 11:26 AM EDT
Terminated Phase 1 Interventional

Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC

NCT03792841
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer, Prostate Cancer
Interventions
acapatamab, Pembrolizumab, Etanercept, Cytochrome P450 (CYP) Cocktail
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older · Male only
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
13
States / cities
Campbell, California • Duarte, California • Long Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Oct 21, 2026, 11:26 AM EDT
Completed Phase 1 Interventional

Effects of AZD1775 on the PK Substrates for CYP3A, CYP2C19, CYP1A2 and on QT Interval in Patients With Advanced Cancer

NCT03333824
View directory record Official record
Conditions
Solid Tumours
Interventions
CYP1A2 (caffeine), CYP2C19 (omeprazole), CYP3A (midazolam), Kytril (granisetron), Wee-1 kinase inhibitor AZD1775
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
7
States / cities
Bingham Farms, Michigan • Detroit, Michigan • Lebanon, New Hampshire + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2019 · Synced Oct 21, 2026, 11:26 AM EDT
Completed Phase 1 Interventional Results available

A Pharmacokinetic Study of RO5185426 in Combination With a Drug Cocktail in Patients With Metastatic Melanoma

NCT01001299
View directory record Official record
Conditions
Malignant Melanoma
Interventions
Drug cocktail, RO5185426
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
5
States / cities
Los Angeles, California • Boston, Massachusetts • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2017 · Synced Oct 21, 2026, 11:26 AM EDT
Not yet recruiting Early Phase 1 Interventional

Immune Checkpoint Inhibitor (ICI)-Drug-Drug Interaction (DDI) Study

NCT07389525
View directory record Official record
Conditions
Gastrointestinal Neoplasms, Genitourinary Cancer, Thoracic Cancer, Sarcoma, Melanoma
Interventions
ICI Therapy
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 21, 2026, 11:26 AM EDT
Completed Phase 1 Interventional Results available

A Study of Ixekizumab in Participants With Plaque Psoriasis

NCT02993471
View directory record Official record
Conditions
Psoriasis
Interventions
Drug Cocktail, Ixekizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
3
States / cities
Anaheim, California • DeLand, Florida • High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 12, 2019 · Synced Oct 21, 2026, 11:26 AM EDT
Completed Early Phase 1 Interventional

Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic Dermatitis

NCT05891119
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Caffeine, Metoprolol, Midazolam, Warfarin, Vitamin K, Omeprazole, Rocatinlimab
Dietary Supplement · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
7
States / cities
North Hollywood, California • DeLand, Florida • Hialeah, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 21, 2026, 11:26 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Evaluating the Pharmacokinetics of Oregano and Potential Oregano-drug Interactions Using a Drug Cocktail Approach

NCT06693960
View directory record Official record
Conditions
Interaction
Interventions
Oregano, Drug cocktail
Dietary Supplement · Drug
Lead sponsor
Washington State University
Other
Eligibility
18 Years to 64 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 21, 2026, 11:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug Interaction Study of LY3871801 in Healthy Participants

NCT05602675
View directory record Official record
Conditions
Healthy
Interventions
LY3871801, Methotrexate, Warfarin, Dextromethorphan, Midazolam, Repaglinide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 21, 2026, 11:26 AM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors

NCT03864042
View directory record Official record
Conditions
Advanced Solid Tumors, Metastatic Melanoma
Interventions
losartan, dextromethorphan, caffeine, omeprazole, midazolam, rosuvastatin, bupropion immediate release (IR), encorafenib, binimetinib, modafinil
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
11
States / cities
Orange, California • Aurora, Colorado • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2024 · Synced Oct 21, 2026, 11:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study on Effects of BMS-955176 on the Pharmacokinetics of Probe Substrates

NCT02578277
View directory record Official record
Conditions
HIV Infections
Interventions
CYP and transporter probe substrates, BMS-955176, BMS-955176 plus CYP and transporter probe substrates
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 50 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 13, 2018 · Synced Oct 21, 2026, 11:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Evaluate The Effect of T89(Dantonic®)On P450 Enzymes

NCT01473888
View directory record Official record
Conditions
Stable Angina
Interventions
T89(Dantonic)
Drug
Lead sponsor
Tasly Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Nov 8, 2012 · Synced Oct 21, 2026, 11:26 AM EDT
Completed Phase 1 Interventional Results available

A Study of Abemaciclib in Participants With Cancer That is Advanced or Has Spread to Another Part(s) of the Body

NCT02688088
View directory record Official record
Conditions
Neoplasm Metastasis
Interventions
Drug Cocktail, Abemaciclib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
5
States / cities
Denver, Colorado • Indianapolis, Indiana • Fairway, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2022 · Synced Oct 21, 2026, 11:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Open Label Study Evaluating the Effects of a Single Oritavancin Infusion on Cytochrome P450 in Healthy Volunteers

NCT01784536
View directory record Official record
Conditions
Healthy
Interventions
Single-Dose IV Oritavancin Diphosphate
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 19, 2023 · Synced Oct 21, 2026, 11:26 AM EDT